ArticleNature2022
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 181 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
181citing papers in PubMed, 1 pooled it
24.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
181 citing papers in PubMed, 1 synthesis or guideline pooled it, 243 citations in OpenAlex.
- A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases.EBioMedicine · 2023Pooled it
- P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy.mAbs · 2026Article
- Investigating CD8 T Cell Exhaustion in Chronic LCMV Infection by Flow Cytometry.Current protocols · 2026Article
- IL-2/CD25 acts within the tumor microenvironment to reprogram tumor-specific cytotoxic CD8Journal for immunotherapy of cancer · 2026Article
- Cytokine fusion proteins for solid tumor therapy: mechanistic insights and clinical advances.Journal of hematology & oncology · 2026Review
- A Tumor-Microenvironment-Responsive Chemically Masked IL‑2 Prodrug Potentiates PD‑1 Checkpoint Blockade and Elicits Robust Antitumor Efficacy.ACS central science · 2026Article
- Tumor-infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions.Cancer · 2026Review
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- Airway immune signatures of protection and disease progression in recent human tuberculosis household contacts.Nature immunology · 2026Article
- Impact of Cistron Topology and Bicistronic Vector Design in the piggyBac Transposon System for Improved Antibody Expression.Biotechnology journal · 2026Article
- Simultaneous TCR and IL-2 agonism selectively enhances epitope-specific CD8 T-cell responses during chronic viral infection.Journal of virology · 2026Article
- Anti-PD1-IL18 immunoconjugate promotes effector T cell-mediated antitumor immunity.Journal for immunotherapy of cancer · 2026Article
- In vivo engineering tumor cells to a universal "all-in-one" cancer vaccine with full antigen spectrum.Science advances · 2026Article
- ATF7ip Inhibits the Tumor Immune Response by Promoting Terminal CD8+ T-cell Exhaustion.Cancer immunology research · 2026Article
- Adaptive resistance in cancer immunotherapy.Cellular & molecular immunology · 2026Review
- Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control.Cancer research communications · 2026Article
- First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.Journal for immunotherapy of cancer · 2026Article
- Bi-functional anti-LAG-3-IL-2c enhances immune checkpoint inhibitor and CAR T-cell therapy for cancer.iScience · 2026Article
- Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression.Cancer cell · 2026Article
- High-avidity TCR signaling induces a distinct KLR-positive exhaustion state in human tumor-infiltrating CD8 T cells associated with immunotherapy response.bioRxiv : the preprint server for biology · 2026Article
121 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
35 authors at 5 institutions in 3 countries.
Laura Codarri Deak *Roche Innovation Center Zurich, Schlieren, Switzerland.ORCID http://orcid.org/0000-0002-9913-9285
Valeria Nicolini *Roche Innovation Center Zurich, Schlieren, Switzerland.
Masao Hashimoto *Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-7120-1390
Maria Karagianni *Roche Innovation Center Zurich, Schlieren, Switzerland.
Petra C SchwalieRoche Innovation Center Basel, Basel, Switzerland.
Laura LauenerRoche Innovation Center Zurich, Schlieren, Switzerland.
Eleni Maria VarypatakiRoche Innovation Center Zurich, Schlieren, Switzerland.
Marine RichardRoche Innovation Center Zurich, Schlieren, Switzerland.
Esther BommerRoche Innovation Center Zurich, Schlieren, Switzerland.
Johannes SamRoche Innovation Center Zurich, Schlieren, Switzerland.ORCID http://orcid.org/0000-0002-7455-0609
Stefanie JollerRoche Innovation Center Zurich, Schlieren, Switzerland.
Mario PerroRoche Innovation Center Zurich, Schlieren, Switzerland.
Floriana CremascoRoche Innovation Center Zurich, Schlieren, Switzerland.
Leo KunzRoche Innovation Center Zurich, Schlieren, Switzerland.
Emilio YanguezRoche Innovation Center Zurich, Schlieren, Switzerland.
Tamara HüsserRoche Innovation Center Zurich, Schlieren, Switzerland.
Ramona SchlenkerRoche Innovation Center Munich, Penzberg, Germany.
Marisa MarianiRoche Innovation Center Zurich, Schlieren, Switzerland.
Vinko TosevskiRoche Innovation Center Zurich, Schlieren, Switzerland.
Sylvia HerterRoche Innovation Center Zurich, Schlieren, Switzerland.
Marina BacacRoche Innovation Center Zurich, Schlieren, Switzerland.
Inja WaldhauerRoche Innovation Center Zurich, Schlieren, Switzerland.ORCID http://orcid.org/0000-0001-8008-8660
Sara ColombettiRoche Innovation Center Zurich, Schlieren, Switzerland.
Xavier GueripelRoche Innovation Center Zurich, Schlieren, Switzerland.
Stephan WullschlegerSwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, EPFL, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-5521-2276
Melanie TichetSwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, EPFL, Lausanne, Switzerland.ORCID http://orcid.org/0000-0001-7128-4061
Douglas HanahanSwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, EPFL, Lausanne, Switzerland.
Haydn T KissickEmory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-7624-5598
Stephane LeclairRoche Innovation Center Munich, Penzberg, Germany.
Anne Freimoser-GrundschoberRoche Innovation Center Zurich, Schlieren, Switzerland.ORCID http://orcid.org/0000-0001-5715-3639
Stefan SeeberRoche Innovation Center Munich, Penzberg, Germany.
Volker TeichgräberRoche Innovation Center Basel, Basel, Switzerland.
Rafi AhmedEmory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-9591-2621
Christian KleinRoche Innovation Center Zurich, Schlieren, Switzerland. christian.klein.ck1@roche.com.ORCID http://orcid.org/0000-0001-7594-7280
Pablo UmañaRoche Innovation Center Zurich, Schlieren, Switzerland. pablo.umana@roche.com.ORCID http://orcid.org/0000-0001-8206-2771
Roche (Switzerland) · CHEmory University · USRoche Pharma AG (Germany) · DELudwig Cancer Research · CHSwiss Cancer Center Léman · CH
Funding
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MIllumina NovaSeq 6000 High Throughput DNA Sequencer for Emory UniversityS10OD026799 · OD · EMORY UNIVERSITY · PI BOSINGER, STEVEN EDWARD · 2019 to 2019
$985kNIH HHS P51 OD011132NIH HHS S10 OD026799
Abstract
Expansion and differentiation of antigen-experienced PD-1
Indexed as
CD8-Positive T-LymphocytesProgrammed Cell Death 1 ReceptorReceptors, Interleukin-2Antibodies, BlockingB7-H1 AntigenInfectionsInterleukin-2Interleukin-2 Receptor alpha SubunitNeoplasmsAntibodies, BlockingB7-H1 AntigenInterleukin-2Interleukin-2 Receptor alpha SubunitProgrammed Cell Death 1 ReceptorReceptors, Interleukin-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.